The Food and Drug Administration (FDA) states that Guillain-Barré Syndrome (GBS) is a potential adverse effect of the Johnson & Johnson COVID-19 vaccine. According to the agency, there have been 100 reports of the rare but serious neurological disorder, following vaccination with said vaccine as of July 13. GBS causes inflammation of the nerves which can lead to sudden muscle weakness and loss of sensation. It can also result in complete paralysis or death in some cases.
In response to the reports, the Centers for Disease Control and Prevention (CDC) officially added GBS as a possible effect of the J&J vaccine. In doing so, the agency admitted that the data “indicates a small possible risk” for people who received the vaccine.
Levin says that the typical progression of GBS starts from the legs before moving up to the arms over a one- to four-week period. He went on to explain that these symptoms can be accompanied by “progressive heaviness and weakness in the legs the arms, and later on, there can be difficulty with swallowing and breathing, but those are unlikely to be initial presentations.”J&J vaccine may cause Guillain-Barré Syndrome, warns FDA – Dr. Eddy Bettermann MD